Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24896679 | 0.86 | NPC1 (0.48) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL858867 | 0.83 | NPC1 (0.67) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL19256696 | 0.79 | NPC1 (0.48) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10286734 | 0.78 | L3MBTL1 (0.48) | NPC1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31429362 | 0.78 | NPC1 (0.46) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31573749 | 0.78 | NPC1 (0.46) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16445216 | 0.77 | ALDH1A1 (0.43) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9948309 | 0.77 | SMN1; SMN2 (0.51) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL19879840 | 0.76 | ALDH1A1 (0.42) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL23850448 | 0.76 | ALDH1A1 (0.35) | NPC1ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12157741-B2 | Macrocyclic inhibitors of DYRK1A | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| EP-3883573-B1 | MACROCYCLIC INHIBITORS OF DYRK1A | DANA FARBER CANCER INST INC (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-118119609-A | Imidazole derivatives and their use as antibiotics | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023285497-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-19 | — | — | WO | disclosed |
| US-20220112201-A1 | MACROCYCLIC INHIBITORS OF DYRK1A | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3883573-A1 | MACROCYCLIC INHIBITORS OF DYRK1A | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| CN-113164475-A | Macrocyclic inhibitors of DYRK1A | 达纳-法伯癌症研究公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | NPC1 1233/4885ALDH1A1 1889/4885KDM4E 2488/4885 |
| US-20220112201-A1 | MACROCYCLIC INHIBITORS OF DYRK1A | RET, DYRK1A, DYRK1B | NPC1 2994/4885ALDH1A1 3723/4885KDM4E 1496/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | NPC1 1190/4885ALDH1A1 2361/4885KDM4E 2733/4885 |
| US-12157741-B2 | Macrocyclic inhibitors of DYRK1A | RET, DYRK1A, DYRK1B | NPC1 2994/4885ALDH1A1 3723/4885KDM4E 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.